Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by KBC Group NV

KBC Group NV raised its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 3,862.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,287 shares of the company's stock after purchasing an additional 101,655 shares during the quarter. KBC Group NV owned 0.08% of Apellis Pharmaceuticals worth $3,328,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Wolverine Asset Management LLC purchased a new position in Apellis Pharmaceuticals in the third quarter valued at approximately $27,000. True Wealth Design LLC acquired a new stake in shares of Apellis Pharmaceuticals in the third quarter worth $27,000. Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $56,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company's stock valued at $130,000 after acquiring an additional 781 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Apellis Pharmaceuticals during the 3rd quarter worth $206,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on APLS shares. Mizuho cut their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a "neutral" rating on the stock in a research report on Thursday, October 24th. Oppenheimer reduced their price target on Apellis Pharmaceuticals from $65.00 to $40.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $26.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, January 29th. William Blair started coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an "outperform" rating on the stock. Finally, Piper Sandler lowered their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a "neutral" rating for the company in a report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $46.71.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 2,170 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $62,279.00. Following the sale, the chief financial officer now directly owns 88,100 shares of the company's stock, valued at $2,528,470. This trade represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Cedric Francois sold 2,824 shares of the business's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total transaction of $83,364.48. Following the transaction, the chief executive officer now directly owns 415,695 shares of the company's stock, valued at approximately $12,271,316.40. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 60,002 shares of company stock worth $1,800,119. 6.80% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS traded up $0.29 during trading hours on Tuesday, reaching $28.78. 1,521,252 shares of the stock were exchanged, compared to its average volume of 1,930,451. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The stock has a market capitalization of $3.58 billion, a P/E ratio of -14.18 and a beta of 0.96. The firm has a 50 day simple moving average of $32.06 and a 200-day simple moving average of $32.63.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business's revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.17) EPS. As a group, sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).